Investor Relations
Partner with
the future.
Savatronic Healthcare Technologies is actively seeking strategic partnerships to scale clinical deployments and accelerate product manufacturing.
Investment Thesis
Why Savatronic Healthcare Technologies?
Addressing the Market Gap
Filling the critical gap in accessible, affordable rehabilitation. Our technology brings clinically informed recovery tools to those who need them most.
Community & Service
Driven by a mission to serve the community, empower local clinics, and significantly improve patient outcomes across the rehabilitation sector.
Impact & Medical Backing
Developing impactful devices in direct connection with, and supported by, medical professionals and leading doctors to ensure clinical efficacy.
Market Opportunity
A large and growing need
NeuroGlow addresses the accelerating demand for affordable, engaging, and data-driven rehabilitation for children and neurological patients.
Total Addressable Market
USD 5.8B
Global neuro-rehabilitation device market by 2032
- •Pediatric rehabilitation
- •Autism therapy
- •Cerebral palsy rehabilitation
- •Stroke recovery
Serviceable Available Market
USD 500M+
India rehabilitation & special education market
- •Autism therapy centers
- •Special schools
- •Neuro & physiotherapy clinics
- •Child development centers
Serviceable Obtainable Market
500+
Institutions targeted over five years
- •150 special schools & autism centers
- •100 neuro rehabilitation clinics
- •100 physiotherapy centers
- •50 hospitals
Five-year revenue target across 500+ institutions: ₹5–10 Crore.
Incubation Status
Incubating at AIC IIT Delhi Sonipat
Savatronic Healthcare Technologies is proud to be supported by the Atal Incubation Centre at IIT Delhi, accelerating our mission to revolutionize accessible rehabilitation.
Road Map
From pilot-ready to market launch
A staged path from a validated prototype to first commercial sales, measured against technology readiness levels.
Pilot Ready Product
Aug – Oct 2026
Build a stable, safe, pilot-ready MVP for real-world rehabilitation use.
- NeuroGlow V1.0
- User manual & therapist guide
- SOPs & safety documentation
- 5–10 stable units
Pilot Testing & Validation
Oct – Nov 2026
Validate NeuroGlow in real clinical environments and collect feedback.
- Pilot deployment report
- Clinical validation report
- 20–30 participants
- Case studies
Product Quality & Manufacturing
Nov – Dec 2026
Iterate on feedback and make the product production and quality ready.
- NeuroGlow V2.0
- BOM & production files
- Quality SOPs & QC checklist
- Packaging & manuals
Market Launch
Jan 2027
Launch to early customers and generate real-world impact.
- First commercial sales
- 10–20 units sold
- 5–10 institutional customers
- Post-sales support system
Strategic Partnerships
Areas of Collaboration
Growth & Development
- Product Development
- Clinical Validation
- Patent Filing
- Manufacturing
- Regulatory Compliance
Mentorship
- MedTech Commercialization
- Business Strategy
- Investor Readiness
Network Access
- Hospitals
- Rehabilitation Centers
- Strategic Partners
- Investors
Funding Goals
How your investment makes an impact
Manufacturing
Scale production of NeuroGlow and Smart Walker for mass deployment.
Regulatory
Build the documentation, testing, and quality systems required for future market approvals.
Team Expansion
Hire specialized engineers and clinical researchers.
Market Entry
Establish distribution channels across South and Southeast Asia.
Get Started
Ready to invest in the future of rehabilitation?
Connect with our team to learn more about investment opportunities, pitch deck, and partnership models.
Schedule a Call